WordNet

of or relating to a catarrh; "catarrhal fever is any of several respiratory or oral diseases of livestock such as bluetongue in horses and sheep"
respiratory disease characterized by inflammation of the lung parenchyma (excluding the bronchi) with congestion caused by viruses or bacteria or irritants

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.

Biedenbach DJ, Farrell DJ, Flamm RK, Liverman LC, McIntyre G, Jones RN.SourceJMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
International journal of antimicrobial agents.Int J Antimicrob Agents.2012 Apr;39(4):321-5. Epub 2012 Feb 4.
JNJ-Q2 is a broad-spectrum fluoroquinolone with bactericidal activity against Gram-positive and Gram-negative pathogens and is currently in clinical development for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin-structure infections. This study deter
PMID 22306239

Hulterström AK, Sellin M, Berggren D.SourceDepartment of Odontology/Dental Technicians Programme, Faculty of Medicine, Umeå University, Sweden. anna.karin.hulterstrom@odont.umu.se
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.APMIS.2012 Mar;120(3):210-4. doi: 10.1111/j.1600-0463.2011.02821.x. Epub 2011 Nov 4.
To explore the colonizing bacterial flora of the nasal septum area, that is mostly afflicted by perforations, 101 healthy police students had swab samples taken from that location. The described culture strategy recovered positive cultures from 95% of the test subjects and from 60% with more than on
PMID 22339678

OKIMOTO Niro,HAYASHI Toshikiyo,NANBA Fumiyo,KISHIMOTO Michihiro,KURIHARA Takeyuki,KAWANAKA Norikuni,MIYASHITA Osamu,TAMADA Sadao
川崎医学会誌 37(1), 57-62, 2011
NAID 110008600588

河野茂,青木信樹,河合伸,二木芳人,渡辺彰,堀誠治,渡辺晋一,戸塚恭一
日本化学療法学会雜誌 = Japanese journal of chemotherapy 58(6), 664-680, 2010-11-10
… The clinical efficacy and safety of pazufloxacin(PZFX), an injectable fluoroquinolone antimicrobial, administered at a dose of 1,000 mg twice daily, were evaluated for 99 subjects with bacterial pneumonia, including severe or intractable pneumonia or that caused by Streptococcus pneumoniae in an open uncontrolled clinical study. … Clinical efficacy rate at the end of treatment was 81.8% (81/99 subjects) in all pneumonia, 76.9% (20/26 subjects) in pneumonia caused by S. …
NAID 10027469199